TITLE:
HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt®)
AUTHORS:
M. C. O. Ezeibe, B. L. Salako, F. I. O. Onyeachonam, A. David, O. O. Aina, E. Herbertson, M. E. Sanda, I. J. Ogbonna, E. Kalu, N. U. Njoku, M. I. Udobi, C. A. Akpan
KEYWORDS:
Antivirt®, Opposite Charges’ Electrostatic Attraction, Continuous Depletion Of HIV-Infection Loads
JOURNAL NAME:
World Journal of AIDS,
Vol.10 No.2,
June
30,
2020
ABSTRACT: In verifying antiretroviral efficacy of a Nigerian broad spectrum
antiviral medicine (Antivirt®), the
Nigerian Institute of Medical Research certified it safe by toxicological test
on laboratory animals, before commencing treatment of three HIV/AIDS patients
whose viral loads varied widely (millions, hundreds of thousands and
thousands). To overcome errors associated with such wide differences in
subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month
of the Antivirt®-treatment, means of ranked viral loads of the
patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of
reducing. From second month of the trial, their viral loads started to reduce,
continuously, so that their infection-reduction rates have been increasing from
that -41.03%, to -38.22% in the second month; 23.98% in the third month; 31.76% in the fourth month and
64.12% after the fifth month.